Apr 3
INNPF · INNOCAN PHARMA Corp
Market Cap
$5.80M
Shares
4.50M
Volume · Oct 26
100
Avg daily vol (15 sessions)
161
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.29
Open$1.29
Day$1.29–1.29
52W close$1.29–12.65
Avg vol 30d234
Short int15 · 0.0% of shares · 1.0d
Short vol100%
DataNov 2020–Oct 2026
Latest documents
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-25.1%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.40M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-89.7%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 25.6 · fear
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−91%
below
Price vs 50-day avg
−62%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−94%
trailing
YTD return
−82%
this year
Relative strength
−100%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $14 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
13
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
263%
annualized · 1-yr
Max drawdown
−98%
past year
ATR
17.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−91%
Bearish
Price vs 50-day avg
−62%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $3 › 200d $14 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of shares out · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $13
vs 200-day avg -91%
vs 50-day avg -62%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
INNPF
this stock
INNOCAN PHARMA Corp
|
$5.80M | — | — | — | 0.0% |
|
PG
PROCTER & GAMBLE Co
|
$383.36B | +15.4% | +3.3% | 24.9 | 1.0% |
|
UL
Unilever PLC
|
$142.12B | +0.9% | — | — | 0.0% |
|
CL
Colgate Palmolive Co
|
$76.76B | +22.2% | +1.7% | 37.7 | 2.2% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$47.40B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| INNPF | -26.3% | -25.9% | -94.2% | -20.4% | -82.2% |
| SPY | -0.1% | 0.0% | +5.8% | +0.4% | +12.2% |
| vs SPY | -26.2% | -25.8% | -100.0% | -20.7% | -94.4% |